Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy

Anti-Cancer Drugs

Volumn 23, Issue 4, 2012, Pages 437-444

  Chen, Ping ^a,b,c   Yu, Jun ^b,c   Chalmers, Brain ^b,c   Drisko, Jeanne ^c   Yang, Jun ^b   Li, Benyi ^b   Chen, Qi ^b,c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

ascorbic acid (ascorbate); autophagy; hydrogen peroxide; prostate cancer; vitamin C

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANDROGEN; ASCORBIC ACID; HYDROGEN PEROXIDE;

ARTICLE; AUTOPHAGY; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC 50; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASCORBIC ACID; AUTOPHAGY; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; HYDROGEN PEROXIDE; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 84858279403     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834fd01f     Document Type: Article

References (71)

1. ACS. Cancer Facts and Figures. American Cancer Society 2011. Available at: http://www.cancer.org/downloads/STT/500809web.pdf. [Accessed 19 August 2011].
2. Woodhouse DL. The action of ascorbic acid on tumour metabolism: a preliminary note on the effects observed following injections into mice with tar-induced neoplasms. Biochem J 1934; 28:1974-1976.
3. Jorissen WP, Belinfante AH. The induced oxidation of lactic acid by ascorbic acid and the cancer problem. Science 1934; 79:13.
4. Cameron E, Campbell A. The orthomolecular treatment of cancer II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 1974; 9:285-315.
5. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1976; 73:3685-3689.
6. Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 1978; 75:4538-4542. (Pubitemid 9028392)
7. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22:118-123. (Pubitemid 36417825)
8. Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M. Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 2006; 174:937-942.
9. McCormick W. Cancer: the preconditioning factor in pathogenesis; a new etiologic approach. Arch Pediatr 1954; 71:313-322.
10. Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 2010; 5:e11414.
11. Levine M, Conry-Cantilena C,Wang Y,Welch RW,Washko PW, Dhariwal KR, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA 1996; 93: 3704-3709. (Pubitemid 26125678)
12. Padayatty SJ, Sun H,Wang Y, Riordan HD, Hewitt SM, Katz A, et al. Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 2004; 140:533-537.
13. Chen Q, Espey MG, Sun AY, Lee JH, Krishna MC, Shacter E, et al. Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci USA 2007; 104:8749-8754. (Pubitemid 47175383)
14. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA 2008; 105:11105-11109.
15. Verrax J, Calderon PB. Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 2009; 47:32-40.
16. Pollard HB, Levine MA, Eidelman O, Pollard M. Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 2010; 24:249-255.
17. Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, et al. Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 2010; 16:509-520.
18. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 2008; 19:1969-1974.
19. Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, et al. Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA 2005; 102:13604-13609. (Pubitemid 41420895)
20. Ohno S, Ohno Y, Suzuki N, Soma G, Inoue M. High-dose vitamin C (ascorbic acid) therapy in the treatment of patients with advanced cancer. Anticancer Res 2009; 29:809-815.
21. Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S. High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 2010; 394:249-253.
22. Ullah MF, Khan HY, Zubair H, Shamim U, Hadi SM. The antioxidant ascorbic acid mobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer. Cancer Chemother Pharmacol 2010; 67:103-110.
23. Gilloteaux J, Jamison JM, Neal DR, Loukas M, Doberzstyn T, Summers JL. Cell damage and death by autoschizis in human bladder (RT4) carcinoma cells resulting from treatment with ascorbate and menadione. Ultrastruct Pathol 2010; 34:140-160.
24. Deubzer B, Mayer F, Kuci Z, Niewisch M, Merkel G, Handgretinger R, Bruchelt G. H(2)O(2)-mediated cytotoxicity of pharmacologic ascorbate concentrations to neuroblastoma cells: potential role of lactate and ferritin. Cell Physiol Biochem 2010; 25:767-774.
25. Carosio R, Zuccari G, Orienti I, Mangraviti S, Montaldo PG. Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer 2007; 6:55.
26. Hong SW, Jin DH, Hahm ES, Yim SH, Lim JS, Kim KI, et al. Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep 2007; 18:811-815.
27. Lin SY, Lai WW, Chou CC, Kuo HM, Li TM, Chung JG, Yang JH. Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res 2006; 16:509-519.
28. Kang JS, Cho D, Kim YI, Hahm E, Yang Y, Kim D, et al. L-ascorbic acid (vitamin C) induces the apoptosis of B16 murine melanoma cells via a caspase-8-independent pathway. Cancer Immunol Immunother 2003; 52:693-698. (Pubitemid 37363640)
29. Ohtani S, Iwamaru A, Deng W, Ueda K,Wu G, Jayachandran G, et al. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res 2007; 67:6293-6303. (Pubitemid 47037512)
30. Verrax J, Delvaux M, Beghein N, Taper H, Gallez B, Buc Calderon P. Enhancement of quinone redox cycling by ascorbate induces a caspase-3 independent cell death in human leukaemia cells. An in vitro comparative study. Free Radic Res 2005; 39:649-657. (Pubitemid 40846837)
31. Verrax J, Cadrobbi J, Marques C, Taper H, Habraken Y, Piette J, Calderon PB. Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis 2004; 9:223-233. (Pubitemid 38987599)
32. Jamison JM, Gilloteaux J, Taper HS, Summers JL. Evaluation of the in vitro and in vivo antitumor activities of vitamin C and K-3 combinations against human prostate cancer. J Nutr 2001; 131:158S-160S. (Pubitemid 32060639)
33. Gilloteaux J, Jamison JM, Arnold D, Ervin E, Eckroat L, Docherty JJ, et al. Cancer cell necrosis by autoschizis: synergism of antitumor activity of vitamin C: vitamin K3 on human bladder carcinoma T24 cells. Scanning 1998; 20:564-575. (Pubitemid 29031300)
34. Gilloteaux J, Jamison JM, Arnold D, Taper HS, Summers JL. Ultrastructural aspects of autoschizis: a new cancer cell death induced by the synergistic action of ascorbate/menadione on human bladder carcinoma cells. Ultrastruct Pathol 2001; 25:183-192. (Pubitemid 32607291)
35. Taper HS, Jamison JM, Gilloteaux J, Gwin CA, Gordon T, Summers JL. In vivo reactivation of DNases in implanted human prostate tumors after administration of a vitamin C/K(3) combination. J Histochem Cytochem 2001; 49:109-120.
36. Jamison JM, Gilloteaux J, Taper HS, Calderon PB, Summers JL. Autoschizis: a novel cell death. Biochem Pharmacol 2002; 63:1773-1783. (Pubitemid 34603442)
37. Cullen JJ. Ascorbate induces autophagy in pancreatic cancer. Autophagy 2010; 6:421-422.
38. Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, et al. GSK-3{beta} promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci 2010; 123:861-870.39 Takahashi Y, Coppola D, Matsushita N, Cualing HD, Sun M, Sato Y, et al. Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis. Nat Cell Biol 2007; 9:1142-1151. (Pubitemid 47500490)
39. Liao X, Tang S, Thrasher JB, Griebling TL, Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Mol Cancer Ther 2005; 4:505-515. (Pubitemid 40601831)
40. Park JG, Kramer BS, Steinberg SM, Carmichael J, Collins JM, Minna JD, Gazdar AF. Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res 1987; 47:5875-5879. (Pubitemid 18018721)
41. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942. (Pubitemid 17027905)
42. Giannattasio S, Gagliardi S, Samaja M, Marra E. Simultaneous determination of purine nucleotides, their metabolites and beta-nicotinamide adenine dinucleotide in cerebellar granule cells by ion-pair high performance liquid chromatography. Brain Res Brain Res Protoc 2003; 10:168-174. (Pubitemid 36143917)
43. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1985; 150:76-85. (Pubitemid 16258399)
44. Hanaichi T, Funahashi A, Fujitsuka N, Yoshimura A, Ito F. Ultrastructural aspects of the capsular cells in frog muscle spindle. Okajimas Folia Anat Jpn 1986; 62:281-293.
45. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17:16-23. (Pubitemid 9239413)
46. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999; 35:403-409. (Pubitemid 29380004)
47. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57:406-412. (Pubitemid 24168617)
48. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43: 1809-1818. (Pubitemid 13122588)
49. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997; 3:402-408. (Pubitemid 27145681)
50. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG. Oxidant injury of cells. DNA strand-breaks activate polyadenosine diphosphate-ribose polymerase and lead to depletion of nicotinamide adenine dinucleotide. J Clin Invest 1986; 77:1312-1320. (Pubitemid 16047155)
51. Lee YJ, Shacter E. Oxidative stress inhibits apoptosis in human lymphoma cells. J Biol Chem 1999; 274:19792-19798.
52. Schraufstatter IU, Hinshaw DB, Hyslop PA, Spragg RG, Cochrane CG. Glutathione cycle activity and pyridine nucleotide levels in oxidant-induced injury of cells. J Clin Invest 1985; 76:1131-1139. (Pubitemid 16225562)
53. Brand KA, Hermfisse U. Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species. FASEB J 1997; 11:388-395. (Pubitemid 27193945)
54. Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci 1999; 24:68-72. (Pubitemid 29346576)
55. Ahmad IM, Aykin-Burns N, Sim JE,Walsh SA, Higashikubo R, Buettner GR, et al. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J Biol Chem 2005; 280:4254-4263.
56. Kroemer G. Mitochondria in cancer. Oncogene 2006; 25:4630-4632. (Pubitemid 44187613)
57. Hyslop PA, Hinshaw DB, Halsey WA Jr., Schraufstatter IU, Sauerheber RD, Spragg RG, et al. Mechanisms of oxidant-mediated cell injury. The glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem 1988; 263: 1665-1675. (Pubitemid 18052113)
58. Comelli M, Di Pancrazio F, Mavelli I. Apoptosis is induced by decline of mitochondrial ATP synthesis in erythroleukemia cells. Free Radic Biol Med 2003; 34:1190-1199. (Pubitemid 36423368)
59. Jungeblut CW. Inactivation of poliomyelitis virus in vitro by crystalline vitamin C (ascorbic acid). J Exp Med 1935; 62:517-521.
60. Klenner FR. The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg 1949; 111:209-214.
61. Cameron E, Pauling L, Leibovitz B. Ascorbic acid and cancer: a review. Cancer Res 1979; 39:663-681. (Pubitemid 9143248)
62. Pauling L. Effect of ascorbic acid on incidence of spontaneous mammary tumors and UV-light-induced skin tumors in mice. Am J Clin Nutr 1991; 54 (6 Suppl):1252S-1255S.
63. Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 1979; 301:687-690. (Pubitemid 10240445)
64. Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 1985; 312:137-141. (Pubitemid 15192859)
65. Gaby AR. Intravenous nutrient therapy: the 'Myers cocktail'. Altern Med Rev 2002; 7:389-403. (Pubitemid 35265408)
66. Lassi K, Dawson NA. Emerging therapies in castrate-resistant prostate cancer. Curr Opin Oncol 2009; 21:260-265.
67. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927; 8:519-530.
68. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25:4633-4646. (Pubitemid 44187614)
69. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005; 65:613-621.
70. Chen Y, McMillan-Ward E, Kong J, Israels SJ, Gibson SB. Oxidative stress induces autophagic cell death independent of apoptosis in transformed and cancer cells. Cell Death Differ 2008; 15:171-182. (Pubitemid 350286185)
71. Wu YT, Tan HL, Huang Q, Kim YS, Pan N, Ong WY, et al. Autophagy plays a protective role during zVAD-induced necrotic cell death. Autophagy 2008; 4:457-466. (Pubitemid 351705142)